Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

NCT02719691 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Solid Tumors

Interventions

DRUG: Alisertib
DRUG: MLN0128

Sponsor

University of Colorado, Denver